Europe
It was a relatively quiet week for clinical trial announcements. Here’s a look.
The stated cause of the suspension of enrollment was the occurrence of two intrathecal catheter-related infections that weren’t related to the drug.
According to a company statement, the three employees are doing well and “improving under the care of their healthcare providers.”
The company said its combination treatment of Imfinzi (durvalumab) plus tremelimumab, an anti-CTLA4 antibody and Imfinzi on its own, did not improve overall survival in patients with this advanced form of bladder cancer.
Life sciences and pharma companies from across the globe strengthen their leadership teams and board with this week’s Movers & Shakers.
Biopharma companies, government regulatory and health agencies and academic centers are stepping forward and working to test or develop vaccines and therapeutics for the disease.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The two companies forged a collaboration to discover and design novel small molecule therapeutics, such as protein degraders, across various therapeutic areas
Life sciences companies from across the globe provide updates on their businesses and pipelines.
On Tuesday, the European Commission gave the green light to the merger following the divestiture of an investigational autoimmune treatment.
PRESS RELEASES